SELECT PUBLICATIONS

BCIRG. Interim analysis of phase III study shows Taxotere^® (docetaxel)-based chemotherapy regimens combined with Herceptin^® (trastuzumab) significantly improved disease free survival in early-stage HER2-positive breast cancer. September 15, 2005. [press release]

Burstein HJ. The distinctive nature of HER2-positive breast cancer. N Engl J Med 2005;353(16):1652-4. No abstract available

Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Abstract 1045.

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005;Abstract 1.